非小细胞肺癌围手术期免疫治疗：难点及破局

近年来，非小细胞肺癌（NSCLC）围术期治疗取得了令人瞩目的进展，以KEYNOTE-671为代表的临床研究将围手术期免疫联合化疗确立为早中期NSCLC的新治疗标准。然而，在这一新兴领域仍有许多问题亟待解答，特别是在驱动基因突变NSCLC患者中的疗效探索，以及新辅助治疗未达到病理学完全缓解（pCR）患者的后续治疗策略优化。

针对这些难题，《NEJM医学前沿》特邀广东省人民医院钟文昭教授撰写述评，深入剖析不同驱动基因突变类型NSCLC患者的新辅助治疗策略及其未来方向，并对术后未获pCR患者的治疗困境提出了创新性见解。

1. Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023;389:491-503.

2. Spicer JD, Garassino MC, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;404:1240-52. 

3. Zhong WZ, Yan HH, Chen KN, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. Signal Transduct Target Ther 2023;8:76.

4. Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: A phase II multicenter study. J Clin Oncol 2024;42:3105-14. 

5. Lv C, Fang W, Wu N, et al. Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. Lung Cancer 2023;178:151-6. 

6. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023;389:1672-84. 

7. Zhang C, Sun YX, Yi DC, et al. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). Cell Rep Med 2024;5:101615. 

8. Nakajima EC, Ren Y, Singh H et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. J Clin Oncol 2022;40 (Suppl_16):9001.

9. Zhao R, Shu Y, Xu W, et al. The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis. Cancer Cell Int 2024;24:361.

10. Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 2024;42:3400-9. 

11. Leonetti A, Minari R, Boni L, et al. Phase II, open-label, single-arm, multicenter study to assess the activity and safety of alectinib as neoadjuvant treatment in surgically resectable stage III ALK-positive NSCLC: ALNEO trial. Clin Lung Cancer 2021;22:473-7. 

12.  Shi L, Gao S, Tong L, et al. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports. Front Oncol 2023;13:1120511.

13. Deutsch JS, Cimino-Mathews A, Thompson E, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med 2024;30:218-28. 

14. Jones DR, Wakelee H, Spicer JD, et al. OA01.03 Association of pathologic regression with EFS in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage NSCLC. J Thor Oncol 2024;19((Suppl_10):S8.

15. 默沙东公司新闻公告. https://www.merck.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-after-neoadjuvant-keytruda-and-chemotherapy-in-patients-with-certain-ty/ (accessed on December 5, 2024).